Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
11th December 2021
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
Print Article
Email Article
Save Article
